Raffaele Califano
ORCID: 0000-0003-2611-5319Also affiliated with University of Manchester, Cancer Research UK Manchester Institute, The Christie NHS Foundation Trust, CRUK Lung Cancer Centre of Excellence
Pilot corpus only
This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.
Indexed papers
Why this DataRank?
An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.
Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.
Read the full methodology →Papers
Driven by 3 papers. Top paper: “Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study”.
Mehmet A. N. Şendur, Delvys Rodríguez‐Abreu, Keunchil Park, Dae Ho Lee, Irfan Çiçin +15 more
W. Victoria Lai, Raffaele Califano, Salma K. Jabbour, Charles M. Rudin, Corinne Faivre‐Finn +8 more
Kayleigh Hill, Min Zhang, Charlotte Poile, Sean Ewings, Essa Y. Baitei +35 more